Tivozanib

CAS No. 475108-18-0

Tivozanib( AV-951 | AV951 | AV 951 )

Catalog No. M14578 CAS No. 475108-18-0

A highly potent inhibitor of pan-VEGFR with IC50s of 60/6.5/15 nM for VEGFR1/2/3.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 58 In Stock
2MG 32 In Stock
5MG 52 In Stock
10MG 72 In Stock
25MG 138 In Stock
50MG 234 In Stock
100MG 419 In Stock
200MG 617 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Tivozanib
  • Note
    Research use only, not for human use.
  • Brief Description
    A highly potent inhibitor of pan-VEGFR with IC50s of 60/6.5/15 nM for VEGFR1/2/3.
  • Description
    A highly potent inhibitor of pan-VEGFR with IC50s of 60/6.5/15 nM for VEGFR1/2/3; also inhibits EphB2, PDGFR-α, PDGFR-β, c-Kit, and Tie2 (IC50=20-80 nM); inhibits VEGF-induced VEGFR-2 phosphorylation in endothelial cells (IC50=0.16 nM); p.o. active.Kidney Cancer Approved.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    AV-951 | AV951 | AV 951
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    EphB2|PDGFRα|VEGFR1|VEGFR2|VEGFR3
  • Research Area
    Cancer
  • Indication
    Kidney Cancer

Chemical Information

  • CAS Number
    475108-18-0
  • Formula Weight
    454.8631
  • Molecular Formula
    C22H19ClN4O5
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    O=C(NC1=NOC(C)=C1)NC2=CC=C(OC3=CC=NC4=CC(OC)=C(OC)C=C34)C=C2Cl
  • Chemical Name
    Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Nakamura K, et al. Cancer Res. 2006 Sep 15;66(18):9134-42. 2. Eskens FA, et al. Clin Cancer Res. 2011 Nov 15;17(22):7156-63. 3. Momeny M, et al. Sci Rep. 2017 Apr 6;7:45954.
molnova catalog
related products
  • 8-O-Acetylshanzhisid...

    8-O-Acetylshanzhiside methylester has potential against cerebral ischemic injury, and its protective effect on oxygen-glucose deprivation-induced injury might be due to the suppression of intracellular Ca2+ elevation and caspase-3 activity.

  • Pazopanib hydrochlor...

    A potent, orally available, pan-VEGFR inhibitor with IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively.

  • Vatalanib free base

    A potent, orally available class III receptor tyrosine kinases inhibitor with IC50 of <1 uM for VEGFR, Flt-1, KDR and PDGFRβ.